Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
---|
CEO | Mr. Mark Paul Lappe |
IPO Date | June 4, 2024 |
Location | United States |
Headquarters | 11025 North Torrey Pines Road |
Employees | 166 |
Sector | Health Care |
Industries |
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Past 5 years
USD 39.01
USD 3.82
USD 5.56
USD 3.29
USD 9.12
USD 36.67
USD 10.53
USD 35.62
USD 8.68
USD 16.86
USD 4.02
USD 20.46
USD 1.60
USD 1.35
USD 1.51
StockViz Staff
January 15, 2025
Any question? Send us an email